Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine, reshaping treatment paradigms across autoimmune disorders, oncology, and infectious diseases. As one of the most versatile and successful therapeutic modalities, monoclonal antibodies continue to dominate biologics pipelines worldwide. However, traditional in-vivo antibody discovery approaches—largely dependent on animal immunization—face increasing limitations, including ethical concerns, time-intensive workflows, high costs, and suboptimal immunogenic responses for certain targets.
In-vitro antibody discovery has emerged as a powerful next-generation alternative. By combining phage display biopanning with next-generation sequencing (NGS), researchers can rapidly screen vast antibody libraries and identify high-affinity binders with greater control, reproducibility, and precision. Yet, the sheer scale and complexity of sequence data generated by NGS introduce new challenges—making data-driven prioritization and optimization critical.
This is where artificial intelligence (AI) becomes transformative.
Excelra’s AI-powered antibody discovery platform integrates machine learning, generative AI, and advanced sequence analytics to significantly enhance in-vitro screening outcomes. By moving beyond traditional enrichment-based selection, the platform enables predictive, data-driven decision-making—reducing experimental cycles while improving binder quality.
In this whitepaper, you will learn:
- How phage display and NGS synergize to identify high-affinity antibodies without the ethical and biological constraints of in-vivo systems
- The science of biopanning, including how iterative selection rounds enrich functional antibody repertoires from large combinatorial libraries
- AbScore, a novel machine learning–derived metric that predicts antibody binding affinity directly from CDR3 amino acid sequences, enabling early and accurate candidate prioritization
- AbGen, a generative AI model that designs de novo CDR3 sequences predicted to exhibit stronger binding than experimentally observed variants
- Excelra’s end-to-end AI-driven workflow, covering in-silico antibody screening, affinity prediction, and rational CDR3 design
- Real-world datasets and validation results demonstrating how AbScore and AbGen improve biopanning efficiency, reduce experimental noise, and accelerate lead identification
Whether you are advancing monoclonal antibody development, optimizing therapeutic antibody libraries, or seeking innovative approaches to high-throughput antibody screening, this whitepaper provides actionable insights grounded in data, biology, and AI.
If your goal is to accelerate antibody discovery timelines, improve hit quality, or reduce costs through machine learning–enabled screening and design, this whitepaper is designed for you.
Download your free copy today to explore how Excelra is redefining in-vitro antibody discovery through artificial intelligence.
Download '.pdf' Format of the whitepaper.
